Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotnib in adults with moderately-to-severely active rheumatoid arthritis with prior inadequate response to methotrexate (FINCH1)

Bibliographic Details
Main Authors:	Taylor, PC, Downie, B, Elboudwarej, E, Kim, S, Hertz, A, Mirza, AM, Siegel, J, Hawtin, RE, Liu, J
Format:	Conference item
Language:	English
Published:	BMJ 2020

Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate (FINCH1)
by: Taylor, P, et al.
Published: (2020)

Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotinib in MTX-naive adults with moderately-to-severely active rheumatoid arthritis (RA) (FINCH3)
by: Taylor, PC, et al.
Published: (2020)

Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Methotrexate Naïve Adults with Moderately-to-severely Active Rheumatoid Arthritis (FINCH3)
by: Taylor, P, et al.
Published: (2020)

Filgotinib, a Janus kinase 1 (JAK1)-selective inhibitor, modulates disease associated cytokines in patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Filgotinib modulates inflammation-associated peripheral blood protein biomarkers in adults with active rheumatoid arthritis and prior inadequate response to methotrexate
by: Tanaka, Y, et al.
Published: (2023)

Selective inhibition of Janus kinase 1 (JAK1) by filgotinib modulates the disease-associated whole blood transcriptional profile of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2019)

Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-07-01)

Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-11-01)

Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo
by: Asmaa Gaber Abdou, et al.
Published: (2018-11-01)

Filgotinib, an oral JAK1 selective inhibitor with a rapid onset of action: results from the DARWIN 1 study in methotrexate inadequate response rheumatoid arthritis patients
by: Taylor, P, et al.
Published: (2017)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022-07-01)

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2024)

Regulation of Voltage Gated K+ Channel KCNE1/KCNQ1 by the Janus Kinase JAK3
by: Jamshed Warsi, et al.
Published: (2015-12-01)

Upregulation of Peptide Transporters PEPT1 and PEPT2 by Janus Kinase JAK2
by: Zohreh Hosseinzadeh, et al.
Published: (2013-05-01)

Patients with high baseline neutrophil-to-lymphocyte ratio exhibit better response to filgotinib as treatment for rheumatoid arthritis
by: Taylor, PC, et al.
Published: (2024)

Patient disease trajectories in baricitinib-treated patients with rheumatoid arthritis and inadequate response to methotrexate
by: Taylor, P, et al.
Published: (2019)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
by: Mark Genovese, et al.
Published: (2018-03-01)

Impact of Janus kinase inhibitors and methotrexate on interstitial lung disease in rheumatoid arthritis patients
by: Shota Kurushima, et al.
Published: (2024-12-01)

Effects of the jak1-selective inhibitor filgotinib on gene expression profile in blood of patients with active rheumatoid
by: Taylor, P, et al.
Published: (2018)

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
by: Bernard G. Combe, et al.
Published: (2022-10-01)

Molecular Characterization and Expression Analysis of Four Janus Kinases (JAK1, JAK2a, JAK3 and TYK2) from Golden Pompano (<i>Trachinotus ovatus</i>)
by: Yushuai Xie, et al.
Published: (2023-05-01)

The JAK1-selective inhibitor filgotinib reverses the disease-associated transcriptional profile found in the blood of patients with active rheumatoid arthritis
by: Taylor, P, et al.
Published: (2018)

Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis
by: Claudio Carini, et al.
Published: (2018-01-01)

Analysis of CR1 Repeats in the Zebra Finch Genome
by: George E. Liu, et al.
Published: (2013-06-01)

More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review’s Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Paul Langley
Published: (2020-01-01)

Methotrexate Is a JAK/STAT Pathway Inhibitor.
by: Sally Thomas, et al.
Published: (2015-01-01)

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
by: Bernard G. Combe, et al.
Published: (2023-01-01)

Efficacy and safety of sarilumab in combination with methotrexate in patients with active rheumatoid arthritis and inadequate effect of methotrexate monotherapy (results of phase III MOBILITY study)
by: E. L. Nasonov, et al.
Published: (2019-05-01)

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
by: Robert Roskoski, Jr.
Published: (2022-09-01)

Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
by: Ulrike Blume-Peytavi, et al.
Published: (2015-04-01)

A subgroup analysis of the efficacy of filgotinib for patients with moderately active RA following an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2021)

Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
by: Yoshiya Tanaka, et al.
Published: (2019-03-01)

Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
by: René Westhovens, et al.
Published: (2021-07-01)

Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry
by: Yoshiya Tanaka, et al.
Published: (2025-01-01)

Janus Particles: 1- Design and Preparation
by: Maede Ramezanpour, et al.
Published: (2022-08-01)

JAK inhibitors in rheumatoid arthritis
by: Taylor, PC
Published: (2019)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.
by: Keystone, E, et al.
Published: (2015)

Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
by: Yoshiya Tanaka, et al.
Published: (2019-04-01)

Tumor necrosis factor inhibitors versus janus kinase inhibitors in patients with incomplete response to methotrexate in rheumatoid arthritis
by: Kunal Chandwar, et al.
Published: (2023-01-01)

A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
by: Walid Fakhouri, et al.
Published: (2020-04-01)

Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotnib in adults with moderately-to-severely active rheumatoid arthritis with prior inadequate response to methotrexate (FINCH1)

Similar Items

Similar Items